Biological therapy with monoclonal antibodies to tumor necrosis factor alpha (TNF-α) was
shown in large clinical trials to be effective in inducing and maintaining clinical remission in …

Background Anti‐tumour necrosis factor (anti‐TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …

Opinion statement Infliximab and adalimumab biosimilars have been approved by the FDA
and European Medicines Agency and have already been introduced to the international …

Biological therapies for inflammatory bowel disease (IBD) have, since their introduction over
15 years ago, been separated from so-called 'conventional therapies' in the therapeutic …

Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …

Background Biological therapies represent a fundamental innovation for the management of
inflammatory bowel diseases (IBD). However, many biological originators have reached, or …

Introduction: Biosimilars are biologic medicines that enter the market subsequent to an
original reference product whose patent has expired. Biosimilar infliximab entered the …

The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

The management of chronic inflammatory disorders including inflammatory bowel diseases
has been revolutionized by the entrance of biological agents now almost 20 years ago. Over …

Background: Biological agents, mainly tumor necrosis factor-α inhibitors, play an important
role in the treatment of inflammatory bowel disease (IBD). These drugs are expensive and …